Mark G. Kris, MD | Authors


Ramucirumab Used to Delay Relapse Following EGFR TKIs in EGFR+ NSCLC

July 12, 2019

Mark G. Kris, MD, discusses the importance of delaying relapse in patients with EGFR-positive non–small cell lung cancer. He shares the significance of the findings from the phase III RELAY trial, where the goal was to delay the time to relapse by adding ramucirumab to erlotinib.